AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.
3 reports, 2 independent
Updated Sep 10
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AC Immune
expertise in the understanding and treatment of neurodegeneration
Nothing else this week.
-
Janssen
company in Cologno Monzese, Italy
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- AC Immune, headquartered in Lausanne, Switzerland, is a company that trades on the Nasdaq exchange and maintains a subsidiary in Boston.
- Eli Lilly and Company announced agreements to acquire potential targets, filing reports with the SEC.
- AC Immune received research funding for clinical trials on June 11th.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- GlobeNewswireAC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executi
- GlobeNewswireAC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunother